Antimicrobials

bioLead and Elitra announce drug discovery and development collaboration

Published in TB and Outbreaks Week, October 22nd, 2002

bioLeads GmbH and Elitra Pharmaceuticals, Inc., announced a risk-sharing collaboration agreement exploiting the combination of bioLeads' natural product identification, isolation, and purification capabilities, along with bioLeads' extensive natural products library, and Elitra's antimicrobial discovery technologies.

Natural products have historically been a very rich source of antimicrobials and are estimated to be the source of over 90% of currently approved antimicrobial drugs.

Under the risk-sharing agreement, Elitra will contribute an unspecified number of proprietary drug targets and related cell-based assays and high throughput screening...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2002-10-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry